Slides
Page 1
© 2 02 5 A l l R i g ht s R e s e r ve d – D oc Go
Page 2
Disclaimer 2© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o Forward-Looking Statements Disclaimer This presentation includes forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including statements reg arding DocGo’s merger with SteadyMD (the “Transaction’), the contingent earn -out consideration, or possible synergies, as well as SteadyMD’s financial condition, projections and results of operations, and the accuracy of any assumptions underlying any of the foregoi ng. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward -looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue relian ce on such statements. All statements other than statements of historical fact are forward -looking, including, but not limited, to statements regarding the Company’s future actions, business strategies or models, plans, goals , future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operat ions, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions. Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause its actual results or outcomes, or the timing of its results or outcomes, to differ materially from those contained in its forward -looking statements, including, but not limited to the foll owing: the risk that the cost savings and synergies from the Transaction may not be fully realized or may take longer than anticipated to be realize; disruption to the parties’ businesses as a result of the Transaction and associated in tegration activities; reputational risk and potential adverse reactions of SteadyMD or DocGo customers, employees, vendors, contractors or other business partners, including those resulting from the announcement or completion of the Transaction; the extent to which SteadyMD’s business will perform consistent with management’s expectations and projections; accuracy of projections; impacts related to accelerated wind down of migrant -related services; unc ertainties related to future non -migrant municipal population health revenue; the Company’s ability to return to profitability and/or expand its programs with insurance partners, hospital systems, municipalities and other strate gic partners; the Company’s ability to successfully implement its business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships and potentially repaying its line of credit; the Company’s ability to establish, maintain and grow customer relationships; the Company’s ability to execute projects to the satisfaction of its customers; the Company’s ability to grow demand for its care gap closure programs; the Company’s ability to maintain or grow its cash balances; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and other strategic partners; the Company’s ability to compete effectivel y in a highly competitive industry, including conditions in the healthcare transportation and mobile health services markets; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts, inclu ding changes in government spending on healthcare and other social services; recent revenue growth derived from a small number of large customers; the Company’s ability to effectively manage its growth; the Company’s financi al performance and future prospects; the Company’s workforce reduction and ability to achieve associated cost savings; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’ s ability to expand geographically; the Company’s M&A activity and success of its acquisition strategy; the Company’s ability to retain its workforce and management personnel and successfully manage leadership transitions; the availa bility of healthcare professionals and other personnel; changes in the cost of labor; the Company’s ability to collect on customer receivables; risks associated with the Company’s share repurchase program; overall macroeconomic and g eopolitical conditions, including the interest rate environment, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a s hutdown of the U.S. federal government; the ability of the Company’s suppliers to meet its needs; the Company’s ability to obtain or maintain operating licenses; potential changes in federal, state or local government policies or priorit ies; expected impacts of geopolitical instability; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; the Company’s ability to improve gross margins; the Company’s a bility to implement and deliver on cost -containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of our stock price; the i mpact on the Company’s business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; the Company’s abil ity to comply with laws and regulations regarding data privacy and protection and other risk factors included in the Company’s filings with the Securities and Exchange Commission (“SEC”). Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge fro m time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward -looking statements contained in this earnings release. The results, events, and circumstances refl ected in the forward -looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward -looking statements. The forward -looking statements made in this earn ings release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward -looking statements made in this presentation reflect events or circum stances after the date of this earnings release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. The Company’s forward -looking statements do not reflect the p otential impact of any future acquisitions, mergers, dispositions, joint ventures or investments. Certain Financial Data & Projections -Related Disclaimer This presentation contains certain financial forecasts related to SteadyMD and the Transaction. These projections have not been audited and should not be relied on as being necessarily indicative of f uture results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in this presentation. Accordingly, there can be no assurance that the prospective results are indicative of future performance of SteadyMD or that actual results, including on a combined basis with DocGo, will not differ materially from those included in this presentation. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.
Page 3
GUY FRIEDMAN CEO & CO-FOUNDER, STEADYMD LEE BIENSTOCK CEO, DOCGO 3© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o
Page 4
Service lines IN-Home Mobile health care Innovative approach using upskilled clinicians to provide care in the comfort of a patient’s home, office or community setting. Leading Provider of technology-enabled mobile healthcare 3,000+ Clinical Staff 900+ Mobile Health Vehicles Medical transportation MANAGEMENT Technology-powered, state-of-the-art fleet and skilled EMS professionals to provide medical transportation and management. Remote Patient Monitoring Empowers care teams with continuous insight into patient health, driving smarter care plans and stronger patient engagement. 10 million+ Patients served since 2015 +92 Patient NPS score Key Customers: Health Systems & Health Plans 31 US states and the UK 4© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o
Page 5
Physicians, PAs and NPs connect virtually with patients and can provide services other vendors cannot Mobile Health Clinicians (MHC) are LPN/LVNs & RNs who travel to patients’ homes and locations with special equipment Innovative Hybrid Care Delivery Model In-person mobile clinician with advanced practice provider on- screen Our providers take a whole -person, preventative care approach, often addressing member education, SDOH (PRAPARE), transportation, care follow up and other needs 5© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o
Page 6
B2B Virtual care platform Provider 900K+ Annual telehealth visits • B2B telehealth in all 50 states • Lab ordering and follow-up care • On-demand urgent care • Virtual primary care • Provider panel with hundreds of board- certified MDs, NPs, and therapists 9 years Operating history Synergistic Services within DocGo's Service Lines $25+ Million 2025E Revenue* EBITDA Projected positive going forward* © 2 0 2 5 A l l R i g ht s R e s e r ve d – D oc Go 6 • Developer-friendly APIs for scale and operational efficiency • White-Label T elehealth Platform • Digital clinic integrated with leading EHRs • Clinical credentialing expertise Integrated Technology Platform SteadyMD provides key infrastructure to its partners: an on-demand clinician workforce, day-to-day clinical operations, and world-class product and technology. 2M+ Annual lab orders * Based on projected, unaudited information available to DocGo and SteadyMD as of the date of this presentation. As of September 30, 2025, SteadyMD recorded revenues of $20 million for the January 1, 2025 - September 30, 2025 period. Inclusion of the prospective financial information in this Presentation should be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. See also the Certain Financial Data & Projections-Related Disclaimer and the Forward-Looking Information Disclaimer included on slide 2 in this presentation. 50 States SteadyMD provides virtual care for top consumer , healthcare and digital wellness brands, including multiple Fortune 10 customers.
Page 7
HOW STEADYMD BENEFITS DOCGO 50-state virtual provider network augment’s DocGo’s in-home care More efficient use of hundreds of telehealth-based providers, potentially garnering up to 10% GM improvement Quicker launch into new geographies due to their scale and presence Ability to cross-sell B2B telehealth services to our partners HOW DOCGO BENEFITS STEADYMD Deployable mobile health resources add new dimension to SteadyMD’s virtual care Immediate expected cost synergies and accretive EBITDA in 2026 Augment services to laboratory customers with in-home phlebotomy & specimen collection Expand virtual primary care service capabilities through in-home medical visits 7© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o
Page 8
advance growth of Quality & Gap Closure programS Primary Care services in the home & virtually SteadyMD’s 50-state virtual care platform streamlines mobile healthcare deployment to new markets Expand home visit scheduling capacity 12 Telehealth to accelerate DocGo’s service offerings Lab Order Approvals + In-Home Phlebotomy SteadyMD’s providers order diagnostics for major lab companies and employers DocGo’s mobile phlebotomy fulfills specimen collection in the home SteadyMD’s providers significantly increase capacity for primary care patients DocGo’s in-home services augment SteadyMD’s primary care practices 8© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o
Page 9
The right vehicle and clinician, at the right time, to the right location, at scale The right clinician for the right patient at the right time, at scale World-class proprietary health tech platforms Both platforms are purpose built to create efficiency in last mile care delivery Optimizes mobile health resource utilization Optimizes clinical resource utilization 9© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o
Page 10
Transaction Overview SteadyMD is expected to generate approximately $25M in 2025 revenue* and is expected to be EBITDA positive for 2026 Target Financials DocGo acquired SteadyMD for up to $25M, comprised of an upfront payment and contingent payment Purchase Price * Based on projected, unaudited information available to DocGo and SteadyMD as of the date of this presentation. As of September 30, 2025, SteadyMD recorded revenues of $20 million for the January 1, 2025 - September 30, 2025 period. Inclusion of the prospective financial information in this Presentation should be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. See also the Certain Financial Data & Projections-Related Disclaimer and the Forward-Looking Information Disclaimer included on slide 2 in this presentation. 10© 2 0 2 5 A l l R i g h t s R e s e r v e d – D o c G o DocGo funded the transaction with cash on hand. Contingent payment to be paid in cash or stock at DocGo’ s election Financing
Page 11
Where homebound patients benefit from onsite treatment, we go. Where long waits in busy emergency rooms do more harm than good, we go. Where underserved populations need better care, we go. Where basic telehealth providers stop, we go. And when all reason says it can’t be done, leave well enough alone and quit while you’re ahead, we do what our company has always done. We go. © 2 0 2 5 A l l R i g ht s R e s e r ve d – D oc Go 11